Thursday, February 5, 2026 at 12:00 PM
Online Streaming Available
February 5th, 2026 1.00 AMA PRA Category 1 Credit Hours
Description
The talk will focus on HPV-negative HNC, where TP53 mutation creates vulnerability to cell cycle active agents. We have explored AURKA targeting in these cancers, and identified enhanced cell cycle arrest as an intrinsic limitation of AURKA inhibition, that however creates dependency on WEE1. We further demonstrate dramatic synergy for AURKA and WEE1 inhibition in combination.
Dates and Times
Start: 2/5/2026 12:00 PM
End: 2/5/2026 1:00 PM
Objectives
1. Understand limitations in targeted therapy of HPV-negative head and neck cancer.
2. Identify targetable vulnerabilities in TP53 mutated HNC.
3. Understand clinical potential of combinations of mitotic entry and checkpoint kinases for TP53 mutated cancer.
Grand Round Files
| File | Link |
|---|---|
|
COI Document Dr. Burtness's staff sent this COI file to have for our records. |
Download |
Speakers
Location
Basic Sciences Tower Level 9, Rm 140
101 Nicolls Rd
Stony Brook , NY 11794
Accreditation
The School of Medicine, State University of New York at Stony Brook, is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
The School of Medicine, State University of New York at Stony Brook designates this live activity for a maximum of 1.00 AMA PRA Category 1 Credits ™. Physicians should only claim the credit commensurate with the extent of their participation in the activity.
Need help with this Grand Round Session?
Please contact the Grand Round coordinator listed below:
Rachel Larin
Department: Pathology Department
Phone: (631) 444-2169
Email: rachel.larin@stonybrookmedicine.edu